Erste Group downgraded AstraZeneca to Hold from Buy. The company recently reported “only mixed results” from a clinical trial in a potential compound to treat lung cancer, the analyst tells investors in a research note. Accordingly, the most important objectives of the study were not achieved with statistical significance, the firm notes.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca says FDA issued a complete response letter for Ultomiris sBLA
- AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia
- Roche downgraded to Neutral from Buy at BofA
- Biden unveils first 10 drugs subject to Medicare price negotiation
- AstraZeneca files challenge to aspects of Inflation Reduction Act